BullFrog AI Holdings has introduced bfARENAS™, a new AI-driven decision engine designed to enhance pharmaceutical portfolio strategy and clinical trial design. This tool helps biotech and pharma companies make clearer, risk-balanced R&D decisions by comparing drug programs and trial designs across multiple strategic scenarios, improving capital efficiency and reducing failure risks. bfARENAS™ integrates with BullFrog's existing AI platforms to provide a comprehensive workflow from data analysis to strategic decision-making. The company will host a webinar on March 27, 2026, to demonstrate bfARENAS™' capabilities and practical applications.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
